trending Market Intelligence /marketintelligence/en/news-insights/trending/p4uz8iqMjPJtJU3IOY1UZw2 content esgSubNav
In This List

Shareholders approve Portage Biotech's acquisition of SalvaRx Group unit

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Shareholders approve Portage Biotech's acquisition of SalvaRx Group unit

Shareholders at SalvaRx Group PLC's annual general meeting have approved a sale of the company's stake in its main operating subsidiary SalvaRx Ltd. to Portage Biotech Inc. for $67.5 million.

The shareholders of Toronto-based biotechnology company Portage Biotech also consented to the acquisition of SalvaRx Group's 94.2% stake on Jan. 8, in exchange for 757,943,784 Portage shares.

Shareholders of U.K.-based SalvaRx Group will receive 660,593,556 Portage shares on a proportional basis.

SalvaRx Ltd. is a holding company that develops therapies within the immuno-oncology market through its subsidiary.